HC Wainwright Reiterates Buy Rating for Talphera (NASDAQ:TLPH)

HC Wainwright restated their buy rating on shares of Talphera (NASDAQ:TLPH) in a report published on Tuesday,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock.

Separately, Maxim Group raised shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Stock Performance

Shares of Talphera stock opened at $0.71 on Tuesday. The stock has a market capitalization of $12.09 million, a PE ratio of -1.03 and a beta of 0.28. Talphera has a 52 week low of $0.50 and a 52 week high of $1.61. The stock has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.82.

Hedge Funds Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC acquired a new position in Talphera, Inc. (NASDAQ:TLPH) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned about 11.73% of Talphera as of its most recent SEC filing. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.